Graybug Vision Inc. (GRAY)

[TruckingAngler]

Holly F’n 100 share GRAY take-down MANIPULATION!!!
GLTA

[TruckingAngler]

Wow how low does GRAY go???
No news.
No financing.
No Pipeline updates???
GLTA

[TruckingAngler]

Thanks RN. Gray’s ridiculous low volume & watching L2 says algo trading having fun. For what though? Volume says barely making few $$???!!

[RNsidersbuying]

GRAY 1.32 - adding heavily here. My crystal ball is showing they should retain approx. $2.70 cash at the Q1-filing all the way down the road in May/22.

How can management, between now and then, ever tout their own stock again while publicly unwilling to buy it at less than .50cents-on-the-dollar?

BV = 3.43 (mostly all cash)

Burn = (.38)

[TruckingAngler]

My adds today were $1.40 also.
1.38 & 1.39 wouldn’t fill…
GLTA

[90 West]

In at 1.4 GLA

[TruckingAngler]

GRAY 1/20/2022: hires 6 new Top-Executives..
This WILL move the needle... Especially with GRAY's crazy LOW-FLOAT !

"Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline. January 20 2022 - 07:30AM. GlobeNewswire Inc.

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug’s Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022.
“We are at a critical stage in our efforts to further progress and diversify our pipeline with new, high-value programs. I strongly believe that strengthening our world-class ophthalmology team is key to our future success. I am therefore pleased to welcome several new team members, who add critical leadership in Regulatory Affairs and Program Management, as well as further deepen our teams’ capabilities in R&D,” said Fred Guerard, Pharm D, CEO of Graybug.

Among Graybug’s key hires are Fang Li, Vice President, Regulatory Affairs, and Ali Kakavand, Vice President, Head of Program Management:

- Fang Li, PhD, RAC, brings over 30 years of drug development and more than 20 years of regulatory affairs experience. She worked across small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products, and medical devices, with a focus on ophthalmology. She has a proven track record in negotiating and gaining regulatory approvals in the US and other regions. Most recently, Fang was VP, Regulatory Affairs at Hurley Consulting Associated, Ltd where she led the regulatory affairs department providing strategic and operational services to clients in the pharmaceutical and biotech industry. Fang holds a doctoral degree in medicinal chemistry from China Pharmaceutical University, Nanjing, a master’s degree in organic chemistry from Wuhan University, and a bachelor's degree in organic chemistry from Xiamen University, P. R. China.

- Ali Kakavand, PhD, has over 20 years of experience in program and project management for the development of medical devices and pharmaceuticals across multiple therapeutic areas. He has extensive knowledge in the management of global clinical studies, device development, clinical manufacturing, as well as regulatory submissions. Most recently, Ali served as Director of Strategy, Program and Portfolio Management at Alexion (acquired by AstraZeneca) managing a first-of-its-kind marketed drug in hematology, as well as a drug/device combination product in phase 1 clinical development. Ali received his PhD in Biomedical Engineering from Arizona State University, where he completed his dissertation conducting research at The Neurosciences Institute in the field of Biomechanics and Neuromuscular Control.

The compensation committee of Graybug’s board of directors granted the six newly-hired employees inducement options to purchase an aggregate of 234,200 shares of Graybug common stock on January 14, 2022, as inducements material to each employee entering employment with Graybug. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.55 per share, which was equal to the closing price of Graybug common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of a stock option agreement covering the grant."

GLTA
.
.
....

[TruckingAngler]

GRAY low-volume take-down continues...
40k trade days make easy back & forth BS...
Let's have some news GRAY

[TruckingAngler]

GRAY low volume take down working.
Again.
News on financing & progress please!
GLTA

[TruckingAngler]

Thanks & have a great weekend!

[StockLogistics]

5 day chart consolidation ends at close of trading, couple that with a big update let’s see it fly from there , biotech is a place investors willing look to be unaffected by vax mandate ruling l, even if in foreign countries

[StockLogistics]

After hours and Tomorrow big chance for news here imo

[TruckingAngler]

GRAY float still only 21mm so should be a non-issue..
Short interest is highest in history..
GLTA

[StockLogistics]

When they announce funding for their research I think, maybe on January 23 when the 3 month chart consolidates, but the funding could be dilutive

[TruckingAngler]

GRAY with new all time lows AGAIN today...
When will GRAY turn

[TruckingAngler]

GRAY day. The sun'l come out tomorrow...
???
GLTA

[StockLogistics]

January 5, no PR, not good, gotta be excited about the new year if you are a CEO

[StockLogistics]

Low float, cup and handle to 12.65 possible, no toxic financing, big year here Vision ‘22

Share Structure

Market Cap Market Cap
41,146,896
01/03/2022
Authorized Shares
Not Available
Outstanding Shares
21,319,635
11/08/2021
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available

[StockLogistics]

This is the day V for vision big story big year begins now

[TruckingAngler]

GRAY lets go !
GLTA

[StockLogistics]

Funding announcement this week, V for Vision

[StockLogistics]

Announcement soon cup and handle big potential vision V 22

[StockLogistics]

Vision with a V, 2020…2

[StockLogistics]

V for vision?

22 is V

[TruckingAngler]

GRAY manipulated down with such Low-volume since July.
GRAY with crazy Low 21m Float has 200% pops when volume hits.
It's about time GRAY...
GLTA
...
...

.....

[StockLogistics]

Funding not yet located for next phase of research, starting to remind me of sphs

[StockLogistics]

Next chart opportunity January 3 6 month consolidation completes

[TruckingAngler]

GRAY's "cup" just spilled out...
What the heck?
STOP selling GRAY !
GLTA

[TruckingAngler]

Thanks SL. We've seen GRAY do it before with this low float so...
GLTA

[StockLogistics]

Looking for a completion of cup and handle to 12.44 minimum on this run, consolidations are over on one and three month chart, SP surge can happen any day, great SS as well, CEO converted to some common stock today but not much, just 5000 shares. Looking good here.

Share Structure

Market Cap Market Cap
47,251,981
12/07/2021
Authorized Shares
Not Available
Outstanding Shares
21,319,635
11/08/2021
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available

https://www.otcmarkets.com/stock/GRAY/security

There is some short interest here too. Numbers are improving for this company.

“ 4:13p ET 11/11/2021 - Benzinga
Graybug Vision Q3 EPS $(0.38) Up From $(2.52) YoY

Graybug Vision (NASDAQ: GRAY) reported quarterly losses of $(0.38) per share. This is a 84.92 percent increase over losses of $(2.52) per share from the same period last year.Graybug Vision (NASDAQ:GRAY) reported quarterly losses of $(0.38) per share. This is a 84.92 percent increase over losses of $(2.52) per share from the same period last year.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

[TruckingAngler]

GRAY earnings today 11/11, and presenting tomorrow 11/12:
"Graybug Vision To Participate In The American Academy Of Ophthalmology 2021 Annual Meeting Nov. 12-15"

"Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held on November 12-15, 2021 in New Orleans, Louisiana, as well as a company presentation at the Eyecelerator@AAO 2021 event on November 11, 2021:

-- Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, to present company overview as part of Retina Showcase at Eyecelerator@AAO 2021 on November 11, 2021, at 2:50 p.m. ET / 1:50 p.m. CT / 11:50 a.m. PT, followed by a panel discussion.

-- Arshad Khanani, MD, MA, to present scientific E-Poster titled "Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2b Trial)". AAO attendees will be able to view E-Poster any time the Exhibit Hall is open from November 12-15. E-Poster will be available for viewing on AAO website after the Annual Session.

-- Veeral Sheth, MD, to present late breaker titled "Intravitreal Sunitinib Malate Depot (GB-102): Durability and Safety in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B)" at AAO Retina Subspecialty Day on November 13, 2021, at 10:02 a.m. ET / 9:02 a.m. CT / 7:02 a.m. PT."

GLTA
..
..

[TruckingAngler]

GRAY volume so low - they manipulate all they want...
Float so low GRAY wll run hard with BUY pressure...
GLTA

[Nebuchadnezzar]

GRAY- looks extremely oversold now



dont know much about the business, so why the massive plunge and then zero bounce since

[TruckingAngler]

Watch for results of GRAY speaking at Cantor Fitzgerald Global Healthcare Conference 9/28.
Imagine the Big Pharma eyes & interest for GRAY's confirmed results 9/28 for "full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD)" along with GRAY's $78.2m on hand at this conference. Big Pharma interest for sure...

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET / 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.

A live webcast of the presentation will be available in the Investors and Media section of the company's website at https://investors.graybug.vision/news-events/events-presentations, with a replay available shortly after the live event.

GLTA
...
.....

[TruckingAngler]

GRAY 9/28: Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
September 28 2021 - 07:30AM.

"Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally.
The ALTISSIMO trial was a masked and controlled Phase 2b dose-ranging study of two doses of GB-102, 1mg and 2mg, with a single control arm of patients on 2mg aflibercept, conducted across 33 study sites in the United States. The primary endpoint was median time to first supportive therapy with a vascular endothelial growth factor (VEGF) inhibitor, and secondary endpoints were safety and pharmacodynamics, measured as mean change in best-corrected visual acuity (BCVA) and mean change in central subfield thickness (CST) of the retina. As previously reported, the development of GB-102 2mg was terminated in 2020 following an interim safety analysis, and ALTISSIMO was not powered to assess non-inferiority to aflibercept.

ALTISSIMO comprised two phases, the first of which was a 12-month treatment phase, or Core Study, in which GB-102 patients were dosed at Day 1 and Month 6, while a control arm received aflibercept every other month. The second phase of ALTISSIMO was a six-month extended observation phase, or Extension Study, in which patients were monitored without additional treatment to determine the duration of effect measured from their last treatment during the Core Study. Participation in the Extension Study was voluntary, but only patients who completed all study visits, and did not require supportive therapy at their Month 12 visit during the Core Study, were eligible. 58% of the patients who completed the Core Study were eligible and agreed to enter the Extension Study, with 11 patients participating in the GB-102 1mg arm.

By its design, patients could not achieve longer than a six-month duration during the Core Study. The Extension Study provided up to an additional six months for patients to demonstrate longer duration, which resulted in 55% of GB-102 1mg patients experiencing a treatment duration of 12 months or longer, while maintaining visual acuity and central retinal thickness. This is the longest duration ever achieved with an intravitreal injection in a randomized, masked, and controlled clinical trial in wet AMD. In addition, the injection burden was reduced by 73% on an annualized basis for those GB-102 1mg patients who participated in the six-month Extension Study.

As in the Core Study, GB-102 1mg continued to be well-tolerated and maintained a favorable safety profile during the Extension Study. No drug-related adverse events or vision-threatening inflammation were reported.

“The Extension Study gave us our first opportunity to see duration beyond six months in a masked and controlled trial, and we are very excited that the majority of patients volunteering for extended observation achieved a treatment duration of 12 months or longer,” said Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug. “Furthermore, the significant reduction in injection burden continued throughout the Extension Study and showed that GB-102 1mg has the potential to significantly improve compliance compared to the current standard of care,” Dr. Zamiri concluded.

Graybug continues to optimize its technology platform and is developing additional formulations that have the potential to preserve the durability of GB-102 1mg microparticles while minimizing the risk of dispersion. These new and enhanced formulations, including injectable implants, may also simplify the drug reconstitution process and the injection technique, both of which are sources of variability in clinical outcomes. These innovations have already been incorporated into the development programs of both GB-102 and GB-401. Graybug anticipates that its GB-401 implant program for glaucoma will enter a Phase 1 trial in the second half of 2022. Given the 12-month or longer duration observed with GB-102 in the ALTISSIMO 18-month trial, Graybug decided to stop the further development of GB-103, which was designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection.

“We are encouraged by the Extension Study data that indicate a class-leading durability of GB-102 1mg of 12 months, or longer,” said Fred Guerard, PharmD, Chief Executive Officer, Graybug Vision. “These data further support the significant commercial opportunity that GB-102 1mg could represent. Our search for a partner to fund the further clinical development of GB-102 is ongoing.”

GLTA
...
...

[TruckingAngler]

GRAY what’s UP after-hours boom???

[Nebuchadnezzar]

yup!! still holding here for $5+ break

[TruckingAngler]

Great to see GRAY 7%+ on such a market RED day...
Hopefully news/update coming...
GRAY float so small we can fly with some BUY pressure !!!
GLTA
...
...

[Nebuchadnezzar]

good morning GRAY

[georgie18]

No position currently...will watch for another entry...

[TruckingAngler]

GRAY looking great again today !
Back to the $15s as lows soon...
GLTA

[georgie18]

Yes Indeed...Psar flipped to a Bullish Buy Position off the $3.50 range bottom...

[TruckingAngler]

GRAY with some pre-market Bid-slappin UP...
Over $4 already...
It's about TIME to return to previous $15 lows as was...
GLTA
>>>
...

[georgie18]

Bidding $3/$3.50…it will find its bottom and reverse …I am patient…

[Nebuchadnezzar]

would like to see some bullish reversal from here

this stock got destroyed. first found it at $4.50 ish

[georgie18]

Been a great trader for me…Nice Grabs in this range…

[TradeSmart.ai]

Agreed

[Nebuchadnezzar]

would be nice. snagged some $3.88s and $3.89s

[TradeSmart.ai]

Bottoming out here

[Nebuchadnezzar]

GRAY- $35 to $3.75.